Evonile Pharma Ltd revises its September 2026 integrated filing, clarifying ₹800 crore in outstanding loans and financial indebtedness
- Correction adds the omitted “INR in crores” label to the outstanding-loans table.
- No defaults were reported.
- Financial figures and other disclosures, including the limited review report and related-party transaction disclosures, remain unchanged.